Literature DB >> 31525673

Computerized cognitive remediation therapy, REHACOM, in first episode of schizophrenia: A randomized controlled trial.

Lorena García-Fernández1, Nuria Cabot-Ivorra2, Victoria Rodríguez-García3, Jorge Pérez-Martín4, Mónica Dompablo5, Bartolomé Pérez-Gálvez6, Roberto Rodriguez-Jimenez7.   

Abstract

Patients with schizophrenia show cognitive impairments that have been linked to poor social functioning. Computerized cognitive remediation therapy has shown to be effective in improving both cognition and functioning in chronic schizophrenia, but relatively little is known about how these approaches improve cognition and functioning when applied to early stages of psychosis. Eighty-six participants with a first episode of psychosis, undergoing a specific program for early stages of schizophrenia, undertook either the REHACOM computerized cognitive remediation intervention (n = 36), or an active control condition (n = 50) consisting in 24 one-hour sessions addressed twice a week. Clinical features, cognition and functioning were assessed at baseline, post-treatment and six months after finishing the intervention. A significant progressive improvement in neurocognition and functioning was globally shown with no differences observed between the experimental and control group at post training or follow up. All cognitive domains but Social Cognition improved between 0.5 and 1 S.D. through the study period. The computerized cognitive remediation therapy REHACOM has not proved to be effective on improving cognition nor functioning compared to controls in outpatients with a first episode of schizophrenia.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31525673     DOI: 10.1016/j.psychres.2019.112563

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  1 in total

1.  Computer-Assisted Cognitive Remediation in Schizophrenia: Efficacy of an Individualized vs. Generic Exercise Plan.

Authors:  Magdalena Bossert; Celina Westermann; Thomas M Schilling; Matthias Weisbrod; Daniela Roesch-Ely; Steffen Aschenbrenner
Journal:  Front Psychiatry       Date:  2020-09-16       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.